https://mil.news.sina.com.cn/china/2020-09-16/doc-iivhuipp4544031.shtml
阿联酋紧急批准使用中国新冠疫苗 一线医务人员接种
2020年09月15日 22:30 观察者网
0
[编译/观察者网 李焕宇]
据阿联酋通讯社9月14日报道，阿联酋卫生和预防部长奥瓦伊斯（bin Nasser Al Owais）宣布该国已紧急批准使用一批新冠疫苗，接种对象是面临感染风险最大的一线医务人员。路透社报道显示，这批疫苗正是由中国国药集团研制的新冠灭活疫苗。
奥瓦伊斯在媒体发布会上证实，临床研究结果以及该疫苗在阿联酋的第一阶段和第二阶段试验结果均表明该疫苗是安全有效的，目前正在大量志愿者身上进行的第三阶段试验进展也非常顺利。
他还强调，紧急授权与现行的法律法规相容，目的在于更快地完成审查许可工作。
阿联酋政府在社交媒体上发布了这则消息
阿联酋新冠疫苗第三阶段临床试验主要研究者纳瓦尔·卡比（Nawal Al Kaabi）博士透露，目前有来自125个国家的31000名志愿者参加了试验。实验团队并未发现严重副作用，仅和其他疫苗一样出现了疲劳、轻微头痛、存在注射部位疼痛等预期中的反应。
她还表示，研究初步结果表明该疫苗产生了抗体，研究团队还把该疫苗在1000名患有慢性疾病的志愿者身上进行了测试，没有发现并发症。卡比博士确认，这批疫苗除了会有选择地提供给一线医务人员，还会有选择地提供给特定人群。
就阿联酋政府紧急批准疫苗一事，卡比博士认为这是合理的决定。因为在新冠肺炎全球大流行的紧急状况下，这批疫苗的安全性和已知的潜在优点超过了它的潜在风险，阿联酋各部门和疫苗厂家也采取了很多措施来保证疫苗的质量、安全性和有效性。
接种疫苗的志愿者 图片来源：阿布扎比新闻办公室
今年6月23日，阿联酋阿布扎比卫生局宣布，由中国国药集团中国生物开发的新冠灭活疫苗将在该地开展国际临床三期试验，这是全球首个新冠灭活疫苗国际临床（三期）试验，目前尚在进行当中。
此前，该疫苗已在中国通过了一期及二期临床试验。前两期试验结果证明了该疫苗的安全性，在28天内接种两剂后，100%的志愿者产生了抗体，没有严重的不良反应。三期临床试验将在阿联酋各地多家医院的志愿者参与下进行。
值得注意的是，眼下阿联酋疫情不容乐观，自九月起该国连续多日日新增病例数超过500，9月12日还创下日增1007例的新纪录。目前，阿联酋累计确诊80940例，死亡401例，累计治愈70635例。
阿联酋疫情爆发以来的日新增病例数 图表来源：worldometers
UAE urgently approves the use of China's new crown vaccine
September 15, 2020 22:30 Observer Network
0
[Compile/Observer Network Li Huanyu]
According to a report by the Emirates News Agency on September 14, the UAE Minister of Health and Prevention, bin Nasser Al Owais, announced that the country has urgently approved the use of a batch of new crown vaccines for the first-line medical staff who are most at risk of infection. Reuters reported that this batch of vaccines is exactly the new crown inactivated vaccine developed by China National Pharmaceutical Group.
Owais confirmed at the media conference that the clinical research results and the results of the first and second phases of the vaccine in the UAE indicate that the vaccine is safe and effective. The third phase is currently being tested on a large number of volunteers. Progress is also very smooth.
He also emphasized that the emergency authorization is compatible with current laws and regulations, and the purpose is to complete the review and permit work faster.
The UAE government posted this news on social media The UAE government posted this news on social media
Dr. Nawal Al Kaabi (Nawal Al Kaabi), the main investigator of the Phase III clinical trial of the new crown vaccine in the United Arab Emirates, revealed that 31,000 volunteers from 125 countries have participated in the trial. The experimental team did not find any serious side effects, and only experienced the expected reactions like fatigue, mild headache, and pain at the injection site like other vaccines.
She also said that the preliminary results of the study showed that the vaccine produced antibodies, and the research team also tested the vaccine on 1,000 volunteers with chronic diseases and found no complications. Dr. Kabi confirmed that this batch of vaccines will not only be selectively provided to frontline medical staff, but will also be selectively provided to specific groups of people.
Regarding the emergency approval of the vaccine by the UAE government, Dr. Kabi believes this is a reasonable decision. Because in the emergency of the global pandemic of new coronary pneumonia, the safety and known potential advantages of this batch of vaccines exceed its potential risks, various departments and vaccine manufacturers in the UAE have also taken many measures to ensure the quality and safety of vaccines. And effectiveness.
Volunteers vaccinated. Image source: Volunteers vaccinated by the Abu Dhabi Press Office. Image source: Abu Dhabi Press Office.
On June 23 this year, the Abu Dhabi Health Bureau of the United Arab Emirates announced that the new crown inactivated vaccine developed by Sinopharm Sinopharm will carry out international clinical trials there. This is the world's first international clinical trial of the new crown inactivated vaccine (3 The trial is currently underway.
Previously, the vaccine has passed Phase I and Phase II clinical trials in China. The results of the first two phases of the test proved the safety of the vaccine. After two doses within 28 days, 100% of the volunteers developed antibodies and there were no serious adverse reactions. Phase III clinical trials will be conducted with the participation of volunteers from many hospitals across the UAE.
It is worth noting that the current situation in the UAE is not optimistic. Since September, the number of new cases in the country has exceeded 500 for several consecutive days. On September 12, it also set a new record of 1,007 cases each day. At present, 80,940 cases have been confirmed in the UAE, 401 cases have died, and 70,635 cases have been cured.
The number of new cases per day since the outbreak in the UAE Chart source: worldometers The number of new cases per day since the outbreak in the UAE Chart source: worldometers
阿联酋紧急批准使用中国新冠疫苗 一线医务人员接种
2020年09月15日 22:30 观察者网
0
[编译/观察者网 李焕宇]
据阿联酋通讯社9月14日报道，阿联酋卫生和预防部长奥瓦伊斯（bin Nasser Al Owais）宣布该国已紧急批准使用一批新冠疫苗，接种对象是面临感染风险最大的一线医务人员。路透社报道显示，这批疫苗正是由中国国药集团研制的新冠灭活疫苗。
奥瓦伊斯在媒体发布会上证实，临床研究结果以及该疫苗在阿联酋的第一阶段和第二阶段试验结果均表明该疫苗是安全有效的，目前正在大量志愿者身上进行的第三阶段试验进展也非常顺利。
他还强调，紧急授权与现行的法律法规相容，目的在于更快地完成审查许可工作。
阿联酋新冠疫苗第三阶段临床试验主要研究者纳瓦尔·卡比（Nawal Al Kaabi）博士透露，目前有来自125个国家的31000名志愿者参加了试验。实验团队并未发现严重副作用，仅和其他疫苗一样出现了疲劳、轻微头痛、存在注射部位疼痛等预期中的反应。
她还表示，研究初步结果表明该疫苗产生了抗体，研究团队还把该疫苗在1000名患有慢性疾病的志愿者身上进行了测试，没有发现并发症。卡比博士确认，这批疫苗除了会有选择地提供给一线医务人员，还会有选择地提供给特定人群。
就阿联酋政府紧急批准疫苗一事，卡比博士认为这是合理的决定。因为在新冠肺炎全球大流行的紧急状况下，这批疫苗的安全性和已知的潜在优点超过了它的潜在风险，阿联酋各部门和疫苗厂家也采取了很多措施来保证疫苗的质量、安全性和有效性。
今年6月23日，阿联酋阿布扎比卫生局宣布，由中国国药集团中国生物开发的新冠灭活疫苗将在该地开展国际临床三期试验，这是全球首个新冠灭活疫苗国际临床（三期）试验，目前尚在进行当中。
此前，该疫苗已在中国通过了一期及二期临床试验。前两期试验结果证明了该疫苗的安全性，在28天内接种两剂后，100%的志愿者产生了抗体，没有严重的不良反应。三期临床试验将在阿联酋各地多家医院的志愿者参与下进行。
值得注意的是，眼下阿联酋疫情不容乐观，自九月起该国连续多日日新增病例数超过500，9月12日还创下日增1007例的新纪录。目前，阿联酋累计确诊80940例，死亡401例，累计治愈70635例。
UAE urgently approves the use of China's new crown vaccine
September 15, 2020 22:30 Observer Network
0
[Compile/Observer Network Li Huanyu]
According to a report by the Emirates News Agency on September 14, the UAE Minister of Health and Prevention, bin Nasser Al Owais, announced that the country has urgently approved the use of a batch of new crown vaccines for the first-line medical staff who are most at risk of infection. Reuters reported that this batch of vaccines is exactly the new crown inactivated vaccine developed by China National Pharmaceutical Group.
Owais confirmed at the media conference that the clinical research results and the results of the first and second phases of the vaccine in the UAE indicate that the vaccine is safe and effective. The third phase is currently being tested on a large number of volunteers. Progress is also very smooth.
He also emphasized that the emergency authorization is compatible with current laws and regulations, and the purpose is to complete the review and permit work faster.
The UAE government posted this news on social media The UAE government posted this news on social media
Dr. Nawal Al Kaabi (Nawal Al Kaabi), the main investigator of the Phase III clinical trial of the new crown vaccine in the United Arab Emirates, revealed that 31,000 volunteers from 125 countries have participated in the trial. The experimental team did not find any serious side effects, and only experienced the expected reactions like fatigue, mild headache, and pain at the injection site like other vaccines.
She also said that the preliminary results of the study showed that the vaccine produced antibodies, and the research team also tested the vaccine on 1,000 volunteers with chronic diseases and found no complications. Dr. Kabi confirmed that this batch of vaccines will not only be selectively provided to frontline medical staff, but will also be selectively provided to specific groups of people.
Regarding the emergency approval of the vaccine by the UAE government, Dr. Kabi believes this is a reasonable decision. Because in the emergency of the global pandemic of new coronary pneumonia, the safety and known potential advantages of this batch of vaccines exceed its potential risks, various departments and vaccine manufacturers in the UAE have also taken many measures to ensure the quality and safety of vaccines. And effectiveness.
Volunteers vaccinated. Image source: Volunteers vaccinated by the Abu Dhabi Press Office. Image source: Abu Dhabi Press Office.
On June 23 this year, the Abu Dhabi Health Bureau of the United Arab Emirates announced that the new crown inactivated vaccine developed by Sinopharm Sinopharm will carry out international clinical trials there. This is the world's first international clinical trial of the new crown inactivated vaccine (3 The trial is currently underway.
Previously, the vaccine has passed Phase I and Phase II clinical trials in China. The results of the first two phases of the test proved the safety of the vaccine. After two doses within 28 days, 100% of the volunteers developed antibodies and there were no serious adverse reactions. Phase III clinical trials will be conducted with the participation of volunteers from many hospitals across the UAE.
It is worth noting that the current situation in the UAE is not optimistic. Since September, the number of new cases in the country has exceeded 500 for several consecutive days. On September 12, it also set a new record of 1,007 cases each day. At present, 80,940 cases have been confirmed in the UAE, 401 cases have died, and 70,635 cases have been cured.
The number of new cases per day since the outbreak in the UAE Chart source: worldometers The number of new cases per day since the outbreak in the UAE Chart source: worldometers
